HK$33.52
1.00%
Hong Kong, Sep 25, 04:00 pm HKT. Closed.
ISIN
KYG549581067
Symbol
3692
Index

Hansoh Pharmaceutical Group Company Target price 2026 - Analyst rating & recommendation

Hansoh Pharmaceutical Group Company Classifications & Recommendation

Buy
93%
Hold
7%

Hansoh Pharmaceutical Group Company Price Target

Target Price HK$46.85
Price HK$33.52
Potential
Number of Estimates 25
25 Analysts have issued a price target Hansoh Pharmaceutical Group Company 2027 . The average Hansoh Pharmaceutical Group Company target price is HK$46.85. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 29 analysts: 27 Analysts recommend Hansoh Pharmaceutical Group Company to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Hansoh Pharmaceutical Group Company stock has an average upside potential 2027 of . Most analysts recommend the Hansoh Pharmaceutical Group Company stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Billion HK$ 17.56 20.24
22.57% 15.25%
EBITDA Margin 39.30% 40.87%
9.73% 4.01%
Net Margin 36.97% 37.79%
3.67% 2.23%

26 Analysts have issued a sales forecast Hansoh Pharmaceutical Group Company 2026 . The average Hansoh Pharmaceutical Group Company sales estimate is

HK$20.2b
unlock
. This is
8.94% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HK$21.4b 15.44%
unlock
, the lowest is
HK$18.9b 1.96%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 HK$17.6b 22.57%
2026
HK$20.2b 15.25%
unlock
2027
HK$22.1b 9.43%
unlock
2028
HK$25.1b 13.52%
unlock
2029
HK$29.6b 17.80%
unlock
2030
HK$33.9b 14.49%
unlock
2031
HK$43.0b 26.79%
unlock
2032
HK$49.1b 14.32%
unlock
2033
HK$54.8b 11.49%
unlock

26 Hansoh Pharmaceutical Group Company Analysts have issued a net profit forecast 2026. The average Hansoh Pharmaceutical Group Company net profit estimate is

HK$7.6b
unlock
. This is
2.00% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HK$9.8b 25.85%
unlock
, the lowest is
HK$4.9b 37.71%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 HK$6.5b 27.07%
2026
HK$7.6b 17.81%
unlock
2027
HK$8.1b 6.36%
unlock
2028
HK$9.2b 12.54%
unlock
2029
HK$13.5b 47.84%
unlock
2030
HK$17.7b 30.85%
unlock
2031
HK$21.1b 19.11%
unlock
2032
HK$24.5b 16.04%
unlock
2033
HK$27.6b 12.65%
unlock

Net Margin

2025 36.97% 3.67%
2026
37.79% 2.23%
unlock
2027
36.73% 2.80%
unlock
2028
36.41% 0.87%
unlock
2029
45.69% 25.49%
unlock
2030
52.22% 14.29%
unlock
2031
49.06% 6.05%
unlock
2032
49.80% 1.51%
unlock
2033
50.31% 1.02%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share HK$ 1.09 1.26
26.74% 15.60%
P/E 26.58
EV/Sales 8.23

26 Analysts have issued a Hansoh Pharmaceutical Group Company forecast for earnings per share. The average Hansoh Pharmaceutical Group Company EPS is

HK$1.26
unlock
. This is
2.33% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
HK$1.62 25.58%
unlock
, the lowest is
HK$0.80 37.98%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 HK$1.09 26.74%
2026
HK$1.26 15.60%
unlock
2027
HK$1.34 6.35%
unlock
2028
HK$1.51 12.69%
unlock
2029
HK$2.23 47.68%
unlock
2030
HK$2.92 30.94%
unlock
2031
HK$3.48 19.18%
unlock
2032
HK$4.04 16.09%
unlock
2033
HK$4.55 12.62%
unlock

P/E ratio

Current 25.98 34.67%
2026
26.58 2.29%
unlock
2027
24.99 5.98%
unlock
2028
22.21 11.12%
unlock
2029
15.02 32.37%
unlock
2030
11.48 23.57%
unlock
2031
9.64 16.03%
unlock
2032
8.31 13.80%
unlock
2033
7.37 11.31%
unlock

Based on analysts' sales estimates for 2026, the Hansoh Pharmaceutical Group Company stock is valued at an EV/Sales of

and an P/S ratio of
10.15
unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 8.97 31.26%
2026
8.23 8.22%
unlock
2027
7.52 8.62%
unlock
2028
6.63 11.91%
unlock
2029
5.63 15.11%
unlock
2030
4.91 12.66%
unlock
2031
3.88 21.13%
unlock
2032
3.39 12.52%
unlock
2033
3.04 10.31%
unlock

P/S ratio

Current 11.05 26.79%
2026
10.15 8.21%
unlock
2027
9.27 8.62%
unlock
2028
8.17 11.91%
unlock
2029
6.93 15.11%
unlock
2030
6.06 12.66%
unlock
2031
4.78 21.13%
unlock
2032
4.18 12.53%
unlock
2033
3.75 10.31%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today